



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

August 5, 2021

9:30 am

OPEN SESSION AGENDA (VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS		
	DR. TAMARA MCCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	GREGORY CENDANA, CONSUMER MEMBER	
STAFF:	SHAUNA WHITE, EXECUTIVE DIRECTOR	
	Karin Barron, Health Licensing Specialist	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
0805-O-01	Approval of the Open Session Meeting Minutes for June 3, 2021	
<u>Consent Agenda</u>	None	
<u>Chairperson</u> <u>Report</u>	Interprofessional Workgroup	Dr. Tamara McCants
Executive Director Report	 Statistical Report on Pharmacy professionals in the District of Columbia Prescription Drug Monitoring Program Updates DCRx (DC Center for Rational Prescribing) 	Dr. Shauna White
<u>Senior Assistant</u> <u>General Counsel</u> <u>Report</u>		
	None	
<u>Subcommittee</u> <u>Reports</u>		
o8o5-O-o2	Legislative and Regulatory Subcommittee Report	Mr. Friedman
0805-O-03	Communications Subcommittee Report	Dr. Ashlee Bow
<u>Matters for</u> Consideration		
o8o5-O-o4	DC Immunization Consent Question Kristen Fink, PharmD, BCPS, BCACP, CDCES Kaiser Permanente (a) Email Communication	
NABP E- Newsletter	July 28, 2021 Reminder – Register for NABP's Upcoming Live Webinar on Biosimilar and Interchangeable Products	Dr. Tamara McCants

<u>Motion to</u> <u>Adjourn the Open</u> <u>Session</u>	"Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2- 575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." ROLL CALL VOTE
Comments from the Public	
	https://nabp.pharmacy/newsroom/news/.
	Note to the Public: To receive weekly updates from NABP, please sign up by using the following link:
	FDA Alerts Health Care Professionals About Chantix Recall Due to Nitrosamine Impurities
	New Survey Results Show Americans Are Prioritizing Cost Over Safety When Buying Medications Online
	New Web Page Promotes NABP President Juran's Drug Importation Initiative
	New NABP Patient Education Kit Allows Boards of Pharmacy, Health Care Providers to Share Important Online Medication Safety Information
	<u>July 21, 2021</u>
	South Carolina's Opioid Emergency Response Team Issues Warning of Counterfeit 'Blue Pills' Circulating in the State
	Pharmacy Has Played a Vital Role in COVID-19 Vaccinations, New Data Highlights
	New FIP Vaccination Handbook for Pharmacists
	New CDC Data Show Record Numbers of Overdose Deaths in 2020
	Former NECC Supervisory Pharmacist Who Sparked Deadly 2012 Meningitis Outbreak Resentenced to Prison

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:_ AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.